Holding Onto Billions, Astellas CEO Hunts for Next Blockbuster

Published: Nov 30, 2016

A $110 million bet on a prostate cancer medicine gave Astellas Pharma Inc. a blockbuster that helped turn it into one of Asia’s most valuable drugmakers. Now, with patent expirations looming in 2019, Chief Executive Officer Yoshihiko Hatanaka is setting off on a hunt for his next best seller.

Armed with about $3.6 billion in cash, the Japanese drugmaker is assessing various investment options.

Back to news